Moderna Pushes FDA on Covid Vaccine Access with Post-Marketing Data

Moderna told FDA it will provide post-marketing data on its Covid-19 vaccines to restore access to a broader population, the company confirmed May 1.

Moderna and FDA are working through the data package. Post-marketing studies are designed to track real-world vaccine safety and long-term performance after initial regulatory clearance. If FDA accepts Moderna’s data case, Covid vaccine eligibility could expand without requiring a new biologics application.

If the package holds up, it sets a procedural precedent. Companies that demonstrate post-market performance may have a faster regulatory path to expanded indications than they’d get filing new applications from scratch. For a vaccine market where access has contracted since peak rollout, that pathway matters.

The talks don’t guarantee an outcome. FDA could request additional data or reject the expansion bid. But Moderna’s willingness to enter formal dialogue signals confidence in its post-marketing data package.

No timeline for a final regulatory decision has been disclosed.

— Sarah Chen